Latest Options News

Cynata Therapeutics reported a $9.39 million net loss for FY2025, slightly improved from the prior year, while progressing multiple clinical trials with key results expected in 2026. The company maintains a solid cash position and funding runway through mid-2026, supported by recent capital raises and an equity subscription agreement.

Steadfast Group has reported a robust 17.2% increase in underlying net profit after tax for FY25, alongside a 14% rise in its fully franked final dividend, underpinned by both organic growth and strategic acquisitions.

Steadfast Group Limited has announced a fully franked ordinary dividend of AUD 0.117 per share for the half-year ending June 2025, accompanied by a Dividend Reinvestment Plan offering a 2.5% discount.

CTI Logistics Limited has announced a fully franked ordinary dividend of AUD 0.055 per share for the half-year ending June 2025, offering shareholders reinvestment and bonus security plans with attractive discounts.

NTAW Holdings reported a slight revenue increase to $538 million for FY2025 but posted a significant net loss of $44 million, driven by a $39 million impairment charge and operational challenges including the loss of Dunlop distribution rights. The company is executing a business reset focusing on inventory, costs, and cash flow.

Aurora Labs reported a 34% increase in loss after tax to $3.75 million for FY2025, alongside a 327% surge in revenue driven by defence contracts and 3D printing services. The company is progressing its micro gas turbine propulsion systems and pursuing aerospace certification to expand its market footprint.

BTC Health Limited reported a remarkable 277% increase in profit after tax to nearly $4 million for FY25, driven by significant fair value gains on its healthcare investments and key contract wins.

Glennon Small Companies Limited reported a robust FY25 with a 232.75% jump in net profit and declared final dividends, while strategically resetting its preference shares amid evolving small-cap market dynamics.

Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.

Global X Management (AUS) Limited has announced updated estimated distribution amounts for three of its ETFs listed on the ASX AQUA Market for the period ending 31 August 2025, alongside key dates for investors to note.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

Icetana Limited posted a $2.9 million net loss for FY2025, with revenues down 49% due to lower non-recurring sales, while recurring SaaS income grew. The company secured a $3.6 million strategic partnership with SoftBank Robotics, strengthening its foothold in Japan.